What is the significance and recommended management for a patient who is HBsAg positive, anti‑HBe positive, and anti‑HBc (total) positive?

HBsAg Reactive, Anti-HBe Reactive, and Anti-HBc Reactive: Chronic HBV Infection in Low Replicative Phase

This serological pattern indicates chronic hepatitis B infection in the anti-HBe positive (HBeAg-negative) phase, which typically represents lower viral replication but requires immediate assessment of HBV DNA levels, ALT, and fibrosis stage to determine treatment necessity.

Serological Interpretation

Your patient's profile shows:

• HBsAg positive = Active chronic HBV infection
• Anti-HBe positive = Seroconversion has occurred from HBeAg to anti-HBe, suggesting immune control phase
• Anti-HBc positive = Past or ongoing HBV infection marker

This pattern most commonly represents HBeAg-negative chronic hepatitis B or inactive carrier state, depending on viral activity 1.

Critical Next Steps: Risk Stratification

You must immediately obtain these tests to determine management:

1. HBV DNA quantification - This is the single most important determinant
2. ALT level - To assess hepatic inflammation
3. Liver fibrosis assessment - Either by elastography (LSM) or biopsy if indicated

Treatment Decision Algorithm

According to the 2025 EASL guidelines 1, treatment decisions follow this hierarchy:

Treat Immediately If:

• HBV DNA >2,000 IU/ml AND ALT >ULN (upper limit of normal) - Strong recommendation 1
• Any detectable HBV DNA with cirrhosis - regardless of ALT level 1
• Any detectable HBV DNA with advanced fibrosis (LSM >8 kPa or Metavir >F3) - regardless of ALT 1

Consider Treatment If:

• HBV DNA <2,000 IU/ml but persistently elevated ALT - though exclude other liver diseases first 1
• Healthcare worker or high transmission risk - target HBV DNA <2,000 IU/ml (or <200 IU/ml for exposure-prone procedures) 1

Monitor Without Treatment If:

• HBV DNA <2,000 IU/ml AND normal ALT AND no significant fibrosis - This represents the "inactive carrier" state

Clinical Significance of Anti-HBe Positivity

The presence of anti-HBe in your patient suggests seroconversion has occurred, which historically correlates with:

• Lower viral replication rates 2
• Better prognosis compared to HBeAg-positive disease 3
• However, 31-37% of anti-HBe positive patients still have detectable HBV DNA 2, and some develop HBeAg-negative chronic hepatitis with active disease

Critical caveat: Anti-HBe positivity does NOT guarantee inactive disease. Research shows that among anti-HBe positive patients with elevated ALT, 57% still have detectable HBV DNA 2. This is why DNA quantification is mandatory.

Common Pitfalls to Avoid

1. Assuming anti-HBe positivity = inactive disease - Always confirm with HBV DNA and ALT
2. Missing HBeAg-negative chronic hepatitis - This variant can be aggressive despite anti-HBe positivity
3. Delaying treatment in cirrhotic patients - Any detectable DNA mandates treatment regardless of ALT 1
4. Ignoring transmission risk - Even with anti-HBe, if DNA >2,000 IU/ml, transmission risk exists 1

Monitoring Strategy

If treatment is not initiated (inactive carrier state), the patient requires:

• HBV DNA and ALT every 3-6 months for the first year
• Annual HBsAg quantification to assess for functional cure potential
• Fibrosis assessment if not already done
• HCC surveillance if cirrhosis or advanced fibrosis present

Prognosis Context

The anti-HBe positive state generally indicates better immune control, but this is a dynamic infection. Viral reactivation can occur, particularly with immunosuppression 1. Long-term antiviral therapy, when indicated, significantly reduces progression to cirrhosis, HCC, and mortality 1.